Prime Medicine (NASDAQ:PRME) Stock Jumps 11.3% – Here’s What Happened

Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report)’s share price was up 11.3% during trading on Wednesday. The stock traded as high as $4.09 and last traded at $4.2730. 260,194 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 3,383,160 shares. The stock had previously closed at $3.84.

Prime Medicine News Roundup

Here’s some of the latest news about PRME:

  • Positive Sentiment: HC Wainwright raised its EPS estimates for multiple periods, including FY2026 to a loss of $0.99 per share from $1.11, and FY2027 to a loss of $0.89 from $0.91. The firm maintained its Buy rating and $8 price target. Prime Medicine coverage
  • Positive Sentiment: HC Wainwright’s Buy rating was also reaffirmed, providing continued analyst support for PRME. Prime Medicine rating reaffirmed
  • Neutral Sentiment: Prime Medicine presented at the Jefferies Global Healthcare Conference; the supplied article entry does not describe specific announcements or new data. Jefferies conference transcript

Analysts Set New Price Targets

A number of equities analysts have commented on PRME shares. BMO Capital Markets began coverage on shares of Prime Medicine in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $9.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Prime Medicine in a report on Friday, September 25th. Jefferies Financial Group restated a “market outperform” rating on shares of Prime Medicine in a report on Monday, September 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prime Medicine in a research report on Monday, August 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Prime Medicine in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.86.

View Our Latest Stock Report on Prime Medicine

Prime Medicine Price Performance

The business has a 50-day moving average of $3.71 and a two-hundred day moving average of $3.51. The company has a market cap of $717.67 million, a P/E ratio of -4.09 and a beta of 2.14.

Prime Medicine (NASDAQ:PRME – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 222.88%. The company had revenue of $4.21 million during the quarter. Equities analysts anticipate that Prime Medicine, Inc. will post -0.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PRME. Bank of America Corp DE purchased a new position in Prime Medicine in the second quarter valued at $3,621,000. BlackRock Inc. purchased a new position in shares of Prime Medicine in the second quarter valued at approximately $35,432,000. Alphabet Inc. acquired a new stake in shares of Prime Medicine in the second quarter valued at about $61,116,000. Redmile Group LLC purchased a new position in Prime Medicine in the 1st quarter worth approximately $5,536,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Prime Medicine in the second quarter valued at about $7,371,000. 70.37% of the stock is owned by institutional investors and hedge funds.

About Prime Medicine

(Get Free Report)

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

See Also

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.